Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SOHO State of the Art Updates and Next Questions: Waldenström Macroglobulinemia - 2021 Update on Management and Future Directions.

Clinical lymphoma, myeloma & leukemia - 1 Jun 2022

Thomas Sheeba K

Abstract excerpt

Waldenstrom macroglobulinemia (WM) is a low-grade B-cell lymphoproliferative disorder. It is defined by having ≥ 10% bone marrow infiltration with lymphoplasmacytic cells and/or an immunoglobulin M (IgM) monoclonal gammopathy of ≥3g/dL. Risk factors include a personal history of IgM MGUS, and a family history of WM or a related disorder. Race, sex, and chronic antigen stimulation also appear to influence risk....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Immunoglobulin M
Share to Lymphoma, B-Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Myeloid Differentiation Factor 88

Share to Rituximab

Share to Waldenstrom Macroglobulinemia

Source

Identifiers

PMID: 34980578
DOI: 10.1016/j.clml.2021.11.014

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SOHO State of the Art Updates and Next Questions: Waldenström Macroglobulinemia - 2021 Update on Management and Future Directions.PMID 34980578Read ↗

SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström Macroglobulinemia.Semantic proximity Read ↗

Waldenström macroglobulinemia: a review of pathogenesis, current treatment, and future prospects.Semantic proximity Read ↗

Current therapy guidelines for Waldenstrom's macroglobulinaemia.Semantic proximity Read ↗

The Direction of Modern Therapies in Waldenström Macroglobulinaemia.Semantic proximity Read ↗

Bing-Neel Syndrome in Waldenström Macroglobulinemia: Updates on Clinical Management and BTK Inhibitor EfficacySemantic proximity Read ↗

How I treat Waldenström macroglobulinemia.Semantic proximity Read ↗

Waldenström macroglobulinemia.Semantic proximity Read ↗

Toward personalized treatment in Waldenström macroglobulinemia.Semantic proximity Read ↗

Clinico-pathologic characteristics, patterns of treatment and outcome of newly diagnosed Waldenströms Macroglobulinemia- a single center real world retrospective analysisSemantic proximity Read ↗

[Clinical characteristics and prognosis of patients with Waldenström macroglobulinemia and its comparison with the Pivotal study].Semantic proximity Read ↗

New treatment strategies for Waldenström macroglobulinemia.Semantic proximity Read ↗

Treatment of patients with Waldenström macroglobulinaemia: clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.